Enhanced ferroptosis sensitivity promotes the formation of highly myopic cataract via the DDR2-Hippo pathway by Dongling Guo, Yu Du, Xin Liu, Dan Li, Ling Wei, Xiangjia Zhu

“…Mechanistically, RNA sequencing of HMC lens epithelial samples identified up-regulated expression of discoidin domain receptor tyrosine kinase 2 (DDR2) as a key factor, which could enhance ferroptosis sensitivity via the Src-Hippo pathway. …”
Get full text

Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM. by Frances M Bashore, Vittorio L Katis, Yuhong Du, Arunima Sikdar, Dongxue Wang, William J Bradshaw, Karolina A Rygiel, Tina M Leisner, Rod Chalk, Swati Mishra, C Andrew Williams, Opher Gileadi, Paul E Brennan, Jesse C Wiley, Jake Gockley, Gregory A Cary, Gregory W Carter, Jessica E Young, Kenneth H Pearce, Haian Fu, Emory-Sage-SGC TREAT-AD Center, Alison D Axtman

“…RNA sequencing and genetic data support spleen tyrosine kinase (SYK) and high affinity immunoglobulin epsilon receptor subunit gamma (FCER1G) as putative targets to be modulated for Alzheimer's disease (AD) therapy. …”
Get full text

Detection of The TNFSF Members BAFF, APRIL, TWEAK and Their Receptors in Normal Kidney and Renal Cell Carcinomas by Vassiliki Pelekanou, George Notas, Katerina Theodoropoulou, Marilena Kampa, Dimitrios Takos, Vassilia-Ismini Alexaki, Jelena Radojicic, Frank Sofras, Andreas Tsapis, Efstathios N. Stathopoulos, Elias Castanas

“…Therapeutic modalities targeting VEGF, PDGF, and c-kit using tyrosine kinase inhibitors and m-TOR using specific biologic factors are in development. …”
Get full text

New therapies in pulmonary arterial hypertension: Recent insights by Giulia Guglielmi, Konstantinos Dimopoulos, S. John Wort

“…Subsequent sections describe treatments that target epigenetic regulators, e.g. poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors and direct BRD4 antagonists, tyrosine kinase inhibitors (Seralutinib), and therapies aimed at inflammation, such as IL-6 inhibitors, CD-20 inhibitors, and monoclonal antibodies that prevent macrophage migration. …”
Get full text

Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? by Howard L Kaufman, Hongbin Wang, Dipongkor Saha, Samuel D Rabkin, Mia Borlongan, Uyen Le, Hans J Nauwynck

“…In this review, we highlight preliminary data with several cytokines and chemokines, including GM-CSF, interleukin 12, FMS-like tyrosine kinase 3 ligand, tumor necrosis factor α, interleukin 2, interleukin 15, interleukin 18, chemokine (C-C motif) ligand 2, chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 4, or their combinations, and show how these payloads can further enhance the antitumor immunity of oHSV. …”
Get full text

Metastatic brain tumors: from development to cutting‐edge treatment by Guilong Tanzhu, Liu Chen, Jiaoyang Ning, Wenxiang Xue, Ce Wang, Gang Xiao, Jie Yang, Rongrong Zhou

“…For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates are effective in BM. …”
Get full text

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells by Masanobu Tsubaki, Taira Matsuo, Rie Komori, Noriaki Nagai, Tetsushi Yamamoto, Shozo Nishida

“…Abstract Background Chronic myeloid leukemia is associated with a more favorable prognosis following treatment with BCR::ABL1 tyrosine kinase inhibitors (TKIs). Nonetheless, about 40% of affected individuals with CML display resistance or intolerance towards BCR::ABL1 TKIs. …”
Get full text

Cytomegalovirus Infection in Patient with Clear Cell Renal Cell Carcinoma by Ikhwan Rinaldi, Abdul Muthalib, Januar Widodo Sutandar, Hendro Adi Kuncoro, Bambang Irawan Harsono, Nelly Susanto, Tjondro Setiawan, Kevin Winston, Idham Rafly Dewantara, Ihya Fakhrurizal Amin, Yuli Maulidiya Shufiyani

“…In this case report, we present the case of a 61-year-old man with clear cell renal cell carcinoma who underwent targeted therapy with the receptor tyrosine kinase (RTK) inhibitor lenvatinib and the mammalian target of rapamycin (mTOR) inhibitor everolimus. …”
Get full text

Sudden Vision Loss Secondary to Optic Nerve Infiltration as a Presenting Symptom of Metastatic Lung Adenocarcinoma by M. M. Shamim, M. Whaley, H. Rana, S. K. Jeffus, S. Bhatti, A. B. Sallam

“…Further investigation into the role of tyrosine kinase inhibitors and radiation therapy in treating intraocular metastasis involving the optic nerve is needed.…”
Get full text

Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study by Ishan Hirji, Jessica Grinspan, Emuella Flood, Diana Chirovsky, Jennifer Devlen, Samuel Wagner, Catherine Davis

“…**Background:** Tyrosine kinase inhibitors (TKIs) have significantly improved survival for patients with chronic myeloid leukemia (CML) but require long-term administration and non-adherence due to regimen requirements has been reported. …”
Get full text

Features of diagnosis and treatment of gastrointestinal stromal tumors by N. I. Bogomolov, T. V. Burdinskaya, M. A. Goncharova, A. G. Goncharov, N. N. Tomskikh

“…Targeted therapy by tyrosine kinase inhibitors was carried out for 14 patients. …”
Get full text

Aggressive Papillary Thyroid Carcinoma Presenting with Metastasis to the Pancreas by Firas Warda, Sam Ho, Enoch Kuo, Dinesh Rao, Marilu Jurado-Flores

“…Surgical resection can be curative and can be followed by radioactive iodine ablation therapy if cancer cells show avidity. Tyrosine kinase inhibitors can be used in refractory disease. …”
Get full text

Promising horizons in achondroplasia along with the development of new drugs by Keiichi Ozono, Takuo Kubota, Toshimi Michigami

“…Additionally in development are a tyrosine kinase inhibitor, a soluble FGFR3, an antibody against FGFR3, meclizine, and the FGF2-aptamer. …”
Get full text

FGFR antagonists restore defective mandibular bone repair in a mouse model of osteochondrodysplasia by Anne Morice, Amélie de La Seiglière, Alexia Kany, Roman H. Khonsari, Morad Bensidhoum, Maria-Emilia Puig-Lombardi, Laurence Legeai Mallet

“…Lastly, we found that treatment with a tyrosine kinase inhibitor (BGJ398, infigratinib) or a C-type natriuretic peptide (BMN111, vosoritide) fully rescued the defective endochondral bone repair observed in Hch mice. …”
Get full text

Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention by Rodrigo Fonseca, Yuan Xiao Zhu, Laura A. Bruins, Joseph Ahmann, Cecilia de Bonolo Campos, Esteban Braggio, Xianfeng Chen, Mariano Arribas, Susie Darvish, Seth Welsh, Erin Meermeier, Kiran K. Mangalaparthi, Richard K. Kandasamy, Greg Ahmann, J. Erin Wiedmeier-Nutor, Akhilesh Pandey, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

“…Upstream signaling pathways, including growth factor receptor tyrosine kinase (RTK) and phosphoinositide-3-kinase (PI3K) were implicated in this dysregulation. …”
Get full text

Antifibrotic Effect of Combination of Nilotinib and Stem Cell-Conditioned Media on CCl4-Induced Liver Fibrosis by Gamal Shiha, Ahmed Nabil, Ahmed Lotfy, Reham Soliman, Ayman A. Hassan, Islam S. Ali, Doaa F. Gad, Faten Zahran

“…Nilotinib is a second-generation tyrosine kinase inhibitor, which showed antifibrotic efficacy. …”
Get full text

PRMT1 Promotes the Self‐renewal of Leukemia Stem Cells by Regulating Protein Synthesis by Min Zhou, Yi Huang, Ping Xu, Shuyi Li, Chen Duan, Xiaoying Lin, Shilai Bao, Waiyi Zou, Jingxuan Pan, Chang Liu, Yanli Jin

“…Abstract The application of tyrosine kinase inhibitors (TKIs) has revolutionized the management of chronic myeloid leukemia (CML). …”
Get full text

How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience by Gustavo Hideki Kawanami, Leopoldo Katsuda, Thiara Barcelos Rocha, Fabio da Silva Yamashiro, Leonardo Pelafsky, Xingshun Qi, Fernando Gomes Romeiro

“…In addition, some clinical and imaging findings can be deemed as predictors of good response to tyrosine kinase inhibitors.…”
Get full text

Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node by Yu Xia, Yu Huang, Zheng Liu, Siyuan Song, Yi Wang, Yi Wang, Jing Luo

“…Further analysis of NGS identified two novel missense mutations, D326E in BTK (Bruton’s tyrosine kinase) at SH2 domain and D251E in EPHA5 (EPH receptor A5), along with other known cancer- associated mutations. …”
Get full text

The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases by Kazuhiro Usui, Tomonori Ushijima, Yoshiaki Tanaka, Chiharu Tanai, Hiromichi Noda, Norifumi Abe, Hajime Horiuchi, Teruo Ishihara

“…Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). …”
Get full text